A Pharmacovigilance Agreement is a legally binding document that clearly defines how safety information will be collected, assessed, exchanged, and reported between partners throughout the product’s life cycle. Its primary purpose is to protect patients and ensure that all parties meet their regulatory obligations, regardless of how tasks are delegated. By establishing standardized timelines, communication channels, and accountability structures, PVAs eliminate gaps, prevent duplicated efforts, and reduce the risk of non-compliance during inspections.

1. Ensuring Compliance With Regulatory Requirements

PV legislation (EU, FDA, GCC, Russia, etc.) mandates that the Marketing Authorization Holder (MAH) remains responsible for all PV obligations—even when tasks are delegated.
A PVA ensures that every party meets timelines and processes for:

• Adverse Event (AE) reporting
• Literature screening
• Periodic safety reporting (PSUR/PBRER)
• Signal detection
• Risk Management Plan actions
• Local safety officer requirements

This protects the MAH from compliance findings during inspections.

2. Clear Allocation of Responsibilities

A PVA defines who does what, including:

• Which party collects AEs
• Which party performs initial case processing
• Who submits ICSRs to authorities and within what timelines
• Who prepares aggregate safety reports
• Who maintains the safety database
• Who handles product quality complaints with potential safety implications

This prevents gaps, overlaps, and misunderstandings.

3. Standardized and Timely Safety Data Exchange

PVAs govern how information flows between partners:

• Format (CIOMS, E2B R3, Excel, email)
• Timelines (e.g., 24 hours for serious AE forwarding)
• Data completeness requirements
• MedDRA coding expectations

This ensures that safety data is consistent, accurate, and compliant across markets.

4. Protection of Patient Safety

By ensuring proper handling of safety information, PVAs:

• Detect risks earlier
• Ensure faster regulatory action when needed
• Support label updates and signal management

Thus, PVAs ultimately protect the patient using the medicinal product.

5. Avoiding Legal and Regulatory Liability

If safety data is not exchanged or reported properly:

• Companies may face fines, product suspension, or inspection findings
• Patients may be harmed
• The MAH may be held legally responsible

A PVA provides legal clarity and reduces liability for all parties.

6. Supporting Business Continuity

PVAs also support:

• Smooth product launches
• Distribution agreements
• Out-licensing / in-licensing partnerships
• Co-development or co-marketing projects

A strong PVA ensures that pharmacovigilance does not interrupt commercial operations.

7. Record for Inspections and Audits

Regulatory inspectors commonly request PVAs.
A well-structured PVA:

• Demonstrates a robust PV system
• Shows delegation of responsibilities is controlled
• Helps partners pass audits more easily

Key Takeaways

• PV Agreements (PVAs) are essential in partnerships where safety responsibilities are shared between companies.
• They ensure regulatory compliance by defining how adverse events and other safety data must be collected, exchanged, and reported.
• Roles and responsibilities are clearly allocated, preventing gaps, duplication, and misunderstandings.
• PVAs establish standardized timelines and communication channels for rapid and accurate safety data flow.
• They play a critical role in protecting patient safety through timely detection and management of risks.
• PVAs reduce legal and regulatory liability, safeguarding companies during audits and inspections.
• They support smooth business operations, including licensing, distribution, and commercialization partnerships.
• Ultimately, PV Agreements function as strategic tools that ensure efficient, compliant, and safe collaboration across the pharmaceutical ecosystem.

Authored By : Hassene Mokaadi, BPharm.-
Senior Project Manager, Baupharma.